Oral magnesium supplementation in patients with essential hypertension.
To elucidate the effects of magnesium on high blood pressure, a 4-week study of oral magnesium supplementation (MgO 1 g/day) was conducted in 21 outpatients with uncomplicated essential hypertension. During the study, blood pressure and intraerythrocyte sodium concentration decreased significantly, and the erythrocyte ouabain-sensitive 22Na efflux rate constant (Kos) and intraerythrocyte magnesium concentration both increased. Serum triglyceride and free fatty acid concentrations were reduced. Furthermore, the elevation in Kos significantly and positively correlated with both the increase in intraerythrocyte magnesium concentration and the decrease in mean blood pressure. There was a significant inverse correlation between the prestudy Kos and the decrease in mean blood pressure. In addition, when patients were divided according to their overall decrease in mean blood pressure, the prestudy intraerythrocyte sodium concentration was significantly higher in patients with a mean blood pressure decrease of more than 7 mm Hg than that of patients whose mean blood pressure decrease was less than 7 mm Hg. These results suggest that oral magnesium supplementation may lower blood pressure through the activation of a cell membrane sodium pump and may reduce serum lipid concentration. It also suggests that the lower the prestudy Kos or the higher the prestudy intraerythrocyte sodium concentration, the more effective the oral magnesium treatment is in lowering blood pressure. Therefore, we concluded that appropriate oral magnesium intake might be effective as a nonpharmacological treatment for essential hypertension.
Motoyama
T
T
First Department of Internal Medicine, Kobe University School of Medicine, Japan.
Sano
H
H
Fukuzaki
H
H
D000284:Administration, Oral; D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D004341:Drug Evaluation; D004910:Erythrocyte Membrane / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008055:Lipids / Q000097:blood; D008274:Magnesium / Q000097:blood; D008277:Magnesium Oxide / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D015222:Sodium Channels / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors
D008055:Lipids; D015222:Sodium Channels; D008277:Magnesium Oxide; D008274:Magnesium